APLS
Apellis Pharmaceuticals, Inc.
No data for this timeframe.
Vol
Inst. Holders9 funds
Inst. Value$602.4M
Inst. Activity4 buys / 1 sells
SEC Reports5
Recent Activity
May 26, 2026
SEC
Apellis Pharmaceuticals filed Form 15-12G to terminate its SEC registration and suspend reporting obligations, effective
15-12G — Impact 6/10
May 14, 2026
SEC
Nasdaq filed a Form 25-NSE to remove Apellis Pharmaceuticals' common stock from listing and registration, effective May
25-NSE — Impact 2/10
May 14, 2026
SEC
Biogen completed its acquisition of Apellis Pharmaceuticals on May 14, 2026, through a tender offer and subsequent merge
8-K — Impact 8/10
May 14, 2026
Insider
WHEELER CRAIG A sold 24,444 shares
Director @ $0.00 ($0.00)
May 14, 2026
Insider
WHEELER CRAIG A sold 15,110 shares
Director @ $0.00 ($0.00)
May 14, 2026
Insider
Baumal Caroline sold 82,500 shares
Chief Medical Officer @ $0.00 ($0.00)
Inst.
NORGES BANK — NEW
1,198,444 shares ($30.1M)
Inst.
BANK OF AMERICA CORP — TRIM
956,773 shares ($24.0M)
Price Targets
Historical data — last covering-analyst action Oct 2024. No current recommendation available.
$40.92 (Oct 2024)
Current $41.03
Low $40.00
Median $41.00
High $41.00
13 analysts
$40.00
$41.00
Analyst Ratings
3Strong Buy
5Buy
19Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 16, 2024 | Scotiabank | INITIATE | Sector Perform |
| Oct 16, 2024 | William Blair | INITIATE | Outperform |
| Sep 24, 2024 | Wells Fargo | MAINTAIN | Equal-Weight → Equal-Weight |
| Sep 23, 2024 | Baird | MAINTAIN | Outperform → Outperform |
| Sep 20, 2024 | Mizuho | MAINTAIN | Neutral → Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.32 ▲ +3.5% | $-0.49 — $-0.16 | 4% YoY | 8 |
| Next Q | $-0.28 ▼ -6.2% | $-0.60 — $-0.10 | -117% YoY | 8 |
| Current FY | $-1.17 ▼ -4.1% | $-2.19 — $-0.38 | -687% YoY | 8 |
| Next FY | $-0.31 ▼ -28.7% | $-2.02 — $0.68 | 73% YoY | 7 |
Latest Reports
NEUTRAL
15-12G
6/10
Apellis Pharmaceuticals filed Form 15-12G to terminate its SEC registration and suspend reporting obligations, effective
May 26, 2026
NEUTRAL
25-NSE
2/10
Nasdaq filed a Form 25-NSE to remove Apellis Pharmaceuticals' common stock from listing and registration, effective May
May 14, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $268.2M | — |
| MORGAN STANLEY | $230.4M | DOUBLED |
| NORGES BANK | $30.1M | NEW |
| BANK OF AMERICA CORP | $24.0M | TRIM |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $16.2M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 14, 2026 | WHEELER CRAIG | U | $0.00 |
| May 14, 2026 | WHEELER CRAIG | D | $0.00 |
| May 14, 2026 | Baumal Caroline | D | $0.00 |
| May 14, 2026 | Walbert Keli | D | $0.00 |
| May 14, 2026 | Chan Gerald | U | $0.00 |
9 institutional holders with $602.4M total value (23,978,928 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, NORGES. Net buying activity: 4 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 10,674,865 | $268.2M | 44.5% | — |
| 2 | MORGAN STANLEY | 9,173,004 | $230.4M | 38.3% | DOUBLED +184.0% |
| 3 | NORGES BANK | 1,198,444 | $30.1M | 5.0% | NEW |
| 4 | BANK OF AMERICA CORP /DE/ | 956,773 | $24.0M | 4.0% | TRIM -35.2% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 644,445 | $16.2M | 2.7% | TRIM -34.6% |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 633,058 | $15.9M | 2.6% | DOUBLED +6478.9% |
| 7 | TWO SIGMA INVESTMENTS, LP | 562,361 | $14.1M | 2.3% | DOUBLED +123.1% |
| 8 | WELLS FARGO & COMPANY/MN | 103,815 | $2.6M | 0.4% | DOUBLED +4115.0% |
| 9 | FMR LLC | 32,163 | $807.9K | 0.1% | ADD +73.8% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 1,198,444 | — | $30.1M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 1,477,525 | 956,773 | -35.2% | $24.0M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 252,068 | 562,361 | +123.1% | $14.1M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 2,463 | 103,815 | +4115.0% | $2.6M | 2025-Q4 |
| FMR LLC | ADD | 18,503 | 32,163 | +73.8% | $807.9K | 2025-Q4 |
| UBS Group AG | TRIM | 4,735,311 | 3,429,905 | -27.6% | $77.6M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 2,426,628 | 1,477,525 | -39.1% | $33.4M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 10,988 | 722,895 | +6478.9% | $16.4M | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | TRIM | 989,143 | 647,082 | -34.6% | $14.6M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 406,913 | 252,068 | -38.1% | $5.7M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 1,043,655 | 2,463 | -99.8% | $55.7K | 2025-Q3 |
| NORGES BANK | EXIT | 2,367,224 | 0 | -100.0% | $0.00 | 2025-Q3 |
| UBS Group AG | ADD | 3,272,194 | 4,735,311 | +44.7% | $82.0M | 2025-Q2 |
| NORGES BANK | NEW | — | 2,367,224 | — | $41.0M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 4,624 | 1,043,655 | +22470.4% | $18.1M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | ADD | 262,904 | 406,913 | +54.8% | $7.0M | 2025-Q2 |
| FMR LLC | NEAR_EXIT | 1,503,209 | 19,292 | -98.7% | $333.9K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 10,988 | — | $190.2K | 2025-Q2 |
| UBS Group AG | ADD | 2,586,739 | 3,272,194 | +26.5% | $71.6M | 2025-Q1 |
| FMR LLC | TRIM | 2,127,665 | 1,503,209 | -29.3% | $32.9M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 262,904 | — | $5.7M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 271,913 | 0 | -100.0% | $0.00 | 2025-Q1 |
| NORGES BANK | EXIT | 1,086,243 | 0 | -100.0% | $0.00 | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 3,389,785 | 9,627,227 | +184.0% | $307.2M | 2024-Q4 |
| UBS Group AG | DOUBLED | 328,184 | 2,586,739 | +688.2% | $82.5M | 2024-Q4 |
15 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 14, 2026 | WHEELER CRAIG A | Director | U | 24,444 | $0.00 | $0.00 |
| May 14, 2026 | WHEELER CRAIG A | Director | D | 15,110 | $0.00 | $0.00 |
| May 14, 2026 | Baumal Caroline | Chief Medical Officer | D | 82,500 | $0.00 | $0.00 |
| May 14, 2026 | Walbert Keli | Director | D | 8,332 | $0.00 | $0.00 |
| May 14, 2026 | Chan Gerald | Director | U | 25,666 | $0.00 | $0.00 |
| May 14, 2026 | Baumal Caroline | Chief Medical Officer | U | 86,525 | $0.00 | $0.00 |
| May 14, 2026 | Baumal Caroline | Chief Medical Officer | A | 41,250 | $0.00 | $0.00 |
| May 14, 2026 | Baumal Caroline | Chief Medical Officer | D | 41,250 | $0.00 | $0.00 |
| May 14, 2026 | Francois Cedric | Chief Executive Officer | U | 425,968 | $0.00 | $0.00 |
| May 14, 2026 | Chan Gerald | Director | D | 3,062 | $0.00 | $0.00 |
| May 14, 2026 | Machiels Alec | Director | U | 384,989 | $0.00 | $0.00 |
| May 14, 2026 | Francois Cedric | Chief Executive Officer | A | 143,750 | $0.00 | $0.00 |
| May 14, 2026 | Francois Cedric | Chief Executive Officer | D | 143,750 | $0.00 | $0.00 |
| May 14, 2026 | Watson David O. | General Counsel | U | 144,517 | $0.00 | $0.00 |
| May 14, 2026 | Francois Cedric | Chief Executive Officer | D | 100,538 | $0.00 | $0.00 |
| May 14, 2026 | Watson David O. | General Counsel | A | 41,250 | $0.00 | $0.00 |
| May 14, 2026 | Watson David O. | General Counsel | D | 41,250 | $0.00 | $0.00 |
| May 14, 2026 | Watson David O. | General Counsel | D | 82,500 | $0.00 | $0.00 |
| May 14, 2026 | WHEELER CRAIG A | Director | D | 28,195 | $0.00 | $0.00 |
| May 14, 2026 | Boucher Kelley | Chief People Officer | U | 127,804 | $0.00 | $0.00 |
| May 14, 2026 | Boucher Kelley | Chief People Officer | A | 15,073 | $0.00 | $0.00 |
| May 14, 2026 | Boucher Kelley | Chief People Officer | D | 15,073 | $0.00 | $0.00 |
| May 14, 2026 | Boucher Kelley | Chief People Officer | D | 32,976 | $0.00 | $0.00 |
| May 14, 2026 | O'Brien Stephanie Monaghan | Director | U | 25,666 | $0.00 | $0.00 |
| May 14, 2026 | O'Brien Stephanie Monaghan | Director | D | 3,062 | $0.00 | $0.00 |
| May 14, 2026 | O'Brien Stephanie Monaghan | Director | D | 17,580 | $0.00 | $0.00 |
| May 14, 2026 | DeLong Mark Jeffrey | Chief Business & Strat Officer | U | 114,591 | $0.00 | $0.00 |
| May 14, 2026 | DeLong Mark Jeffrey | Chief Business & Strat Officer | A | 41,250 | $0.00 | $0.00 |
| May 14, 2026 | DeLong Mark Jeffrey | Chief Business & Strat Officer | D | 41,250 | $0.00 | $0.00 |
| May 14, 2026 | DeLong Mark Jeffrey | Chief Business & Strat Officer | D | 82,500 | $0.00 | $0.00 |
| May 14, 2026 | Walbert Keli | Director | U | 17,051 | $0.00 | $0.00 |
| May 14, 2026 | Walbert Keli | Director | D | 14,684 | $0.00 | $0.00 |
| May 14, 2026 | Nicholson Nur | Chief Technical Officer | U | 116,338 | $0.00 | $0.00 |
| May 14, 2026 | Nicholson Nur | Chief Technical Officer | A | 22,610 | $0.00 | $0.00 |
| May 14, 2026 | Nicholson Nur | Chief Technical Officer | D | 22,610 | $0.00 | $0.00 |
| May 14, 2026 | Nicholson Nur | Chief Technical Officer | D | 82,500 | $0.00 | $0.00 |
| May 14, 2026 | Chan Gerald | Director | D | 17,580 | $0.00 | $0.00 |
| May 14, 2026 | Chopas James George | VP/Chief Accounting Officer | A | 5,625 | $0.00 | $0.00 |
| May 14, 2026 | Deschatelets Pascal | Chief Scientific Officer | U | 1,177,222 | $0.00 | $0.00 |
| May 14, 2026 | Deschatelets Pascal | Chief Scientific Officer | A | 41,250 | $0.00 | $0.00 |
| May 14, 2026 | Deschatelets Pascal | Chief Scientific Officer | D | 41,250 | $0.00 | $0.00 |
| May 14, 2026 | Deschatelets Pascal | Chief Scientific Officer | D | 108,622 | $0.00 | $0.00 |
| May 14, 2026 | Machiels Alec | Director | D | 3,062 | $0.00 | $0.00 |
| May 14, 2026 | Machiels Alec | Director | D | 17,580 | $0.00 | $0.00 |
| May 14, 2026 | Sullivan Timothy Eugene | Chief Financial Officer | U | 140,945 | $0.00 | $0.00 |
| May 14, 2026 | Sullivan Timothy Eugene | Chief Financial Officer | A | 41,250 | $0.00 | $0.00 |
| May 14, 2026 | Sullivan Timothy Eugene | Chief Financial Officer | D | 41,250 | $0.00 | $0.00 |
| May 14, 2026 | Sullivan Timothy Eugene | Chief Financial Officer | D | 232,903 | $0.00 | $0.00 |
| May 14, 2026 | FONTEYNE PAUL R. | Director | U | 30,666 | $0.00 | $0.00 |
| May 14, 2026 | FONTEYNE PAUL R. | Director | D | 3,062 | $0.00 | $0.00 |
5 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 1 mixed, 3 neutral. Avg impact: 4.8/10.
NEUTRAL
15-12G
6/10
Apellis Pharmaceuticals filed Form 15-12G to terminate its SEC registration and suspend reporting ob
May 26, 2026
NEUTRAL
25-NSE
2/10
Nasdaq filed a Form 25-NSE to remove Apellis Pharmaceuticals' common stock from listing and registra
May 14, 2026
BULLISH
8-K
8/10
Biogen completed its acquisition of Apellis Pharmaceuticals on May 14, 2026, through a tender offer
May 14, 2026
NEUTRAL
8-K
2/10
Apellis Pharmaceuticals amended its Executive Separation Benefits and Retention Plan in connection w
May 4, 2026
MIXED
INST-CLUSTER
6/10
In Q4 2024, Apellis Pharmaceuticals (APLS) saw a mixed institutional cluster: two mega-passive firms
Mar 27, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Oct 2024): 30% buy across 27 analysts — 3 strong buy, 5 buy, 19 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Oct 2024. No current recommendation available.
$40.92 mean target (Oct 2024)
$40.00 Low
$41.00 High
| Metric | Value |
|---|---|
| Current Price | $41.03 |
| Target Low | $40.00 |
| Target Mean | $40.92 |
| Target Median | $41.00 |
| Target High | $41.00 |
| # Analysts | 13 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.32 | $-0.49 | $-0.16 | 3.8% | +3.5% | 0↑ 2↓ | $0.2B | 17.6% | 8 |
| Next Q 2026-09-30 |
$-0.28 | $-0.60 | $-0.10 | -116.8% | -6.2% | 1↑ 1↓ | $0.2B | -52.2% | 8 |
| Current FY 2026-12-31 |
$-1.17 | $-2.19 | $-0.38 | -686.9% | -4.1% | 2↑ 1↓ | $0.9B | -7.9% | 8 |
| Next FY 2027-12-31 |
$-0.31 | $-2.02 | $0.68 | 73.2% | -28.7% | 3↑ 2↓ | $1.0B | 11.2% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.318 | |
| 7d ago | $-0.329 | +0.012 |
| 30d ago | $-0.329 | +0.012 |
| 60d ago | $-0.309 | -0.008 |
| 90d ago | $-0.353 | +0.035 |
16 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 3 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Oct 16, 2024 | Scotiabank | INITIATE | — | Sector Perform |
| Oct 16, 2024 | William Blair | INITIATE | — | Outperform |
| Sep 24, 2024 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| Sep 23, 2024 | Baird | MAINTAIN | Outperform | Outperform |
| Sep 20, 2024 | Mizuho | MAINTAIN | Neutral | Neutral |
| Sep 20, 2024 | Needham | REITERATE | Buy | Buy |
| Sep 13, 2024 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Aug 13, 2024 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Aug 9, 2024 | UBS | MAINTAIN | Buy | Buy |
| Aug 9, 2024 | Wedbush | MAINTAIN | Neutral | Neutral |
| Aug 9, 2024 | Goldman Sachs | MAINTAIN | Buy | Buy |
| Aug 9, 2024 | Baird | MAINTAIN | Outperform | Outperform |
| Aug 9, 2024 | Needham | REITERATE | Buy | Buy |
| Aug 2, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Aug 2, 2024 | Goldman Sachs | MAINTAIN | Buy | Buy |
| Aug 2, 2024 | Needham | REITERATE | Buy | Buy |
| Jul 31, 2024 | Jefferies | MAINTAIN | Buy | Buy |
| Jul 26, 2024 | Baird | MAINTAIN | Outperform | Outperform |
| Jul 23, 2024 | Baird | MAINTAIN | Outperform | Outperform |
| Jul 17, 2024 | Goldman Sachs | MAINTAIN | Buy | Buy |
| Jun 28, 2024 | Baird | MAINTAIN | Outperform | Outperform |
| May 31, 2024 | Piper Sandler | INITIATE | — | Neutral |
| May 28, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 23, 2024 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| May 8, 2024 | Citigroup | MAINTAIN | Buy | Buy |
| May 8, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 8, 2024 | UBS | MAINTAIN | Buy | Buy |
| May 8, 2024 | Needham | REITERATE | Buy | Buy |
| Apr 29, 2024 | Mizuho | MAINTAIN | Neutral | Neutral |
| Apr 26, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 25, 2024 | Needham | REITERATE | Buy | Buy |
| Apr 17, 2024 | Wedbush | MAINTAIN | Neutral | Neutral |
| Apr 15, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 9, 2024 | Needham | REITERATE | Buy | Buy |
| Mar 27, 2024 | Mizuho | MAINTAIN | Neutral | Neutral |
| Mar 6, 2024 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Mar 4, 2024 | UBS | MAINTAIN | Buy | Buy |
| Feb 28, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 28, 2024 | Wedbush | MAINTAIN | Neutral | Neutral |
| Feb 16, 2024 | Mizuho | MAINTAIN | Neutral | Neutral |
| Feb 6, 2024 | Baird | REITERATE | Outperform | Outperform |
| Feb 5, 2024 | Jefferies | UPGRADE | Hold | Buy |
| Jan 30, 2024 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Jan 24, 2024 | Needham | MAINTAIN | Buy | Buy |
| Jan 17, 2024 | Baird | MAINTAIN | Outperform | Outperform |
| Jan 17, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 12, 2024 | Wedbush | MAINTAIN | Neutral | Neutral |
| Jan 11, 2024 | Raymond James | MAINTAIN | Strong Buy | Strong Buy |
| Jan 9, 2024 | Goldman Sachs | MAINTAIN | Buy | Buy |
| Dec 15, 2023 | Citigroup | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 5 | 19 | 0 | 0 | 30% | |
| May 1, 2026 | 3 | 5 | 19 | 0 | 0 | 30% | |
| Apr 1, 2026 | 3 | 9 | 15 | 0 | 0 | 44% | |
| Mar 1, 2026 | 8 | 12 | 8 | 1 | 0 | 69% | |
| Feb 1, 2026 | 8 | 12 | 7 | 1 | 0 | 71% | |
| Jan 1, 2026 | 7 | 12 | 8 | 1 | 0 | 68% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
Recent Reddit Threads
Market Close Report - Tuesday, March 31, 2026
▲ 1
💬 0
⚡ 0.5
Jun 5, 2026
Clinical Trial
Pegcetacoplan Long Term Safety and Efficacy Extension Study
Phase Phase 3 — COMPLETED
May 11, 2026
dark_pool
Dark Pool: APLS — 13.4M shares, 34,348 trades
Week starting 2026-05-11. Total ATS volume: 13,393,774 shares across 34,348 trades.
May 5, 2026
earnings_calendar
APLS Q1 2026 Earnings Scheduled — 2026-05-05
May 4, 2026
short_interest
FTD: APLS — 33,636 shares ($1.4M) failed to deliver
Settlement: 20260504, Price: $40.96, FTD Value: $1,377,730.56, APELLIS PHARMACEUTICALS INC CO
May 4, 2026
dark_pool
Dark Pool: APLS — 4.4M shares, 25,576 trades
Week starting 2026-05-04. Total ATS volume: 4,377,894 shares across 25,576 trades.
Apr 30, 2026
earnings_calendar
APLS Q1 2026 Earnings Scheduled — 2026-04-30
Apr 30, 2026
short_interest
FTD: APLS — 28,566 shares ($1.2M) failed to deliver
Settlement: 20260430, Price: $40.95, FTD Value: $1,169,777.7, APELLIS PHARMACEUTICALS INC CO
Apr 29, 2026
short_interest
FTD: APLS — 555,013 shares ($22.7M) failed to deliver
Settlement: 20260429, Price: $40.99, FTD Value: $22,749,982.87, APELLIS PHARMACEUTICALS INC CO
Apr 27, 2026
dark_pool
Dark Pool: APLS — 1.9M shares, 22,743 trades
Week starting 2026-04-27. Total ATS volume: 1,928,228 shares across 22,743 trades.
Apr 24, 2026
short_volume
Short Volume: APLS — 55.0% short (0.3M / 0.6M)
Short: 317,489 | Exempt: 0 | TRF Vol: 577,020 | Short Ratio: 55.0% | Off-exchange volume (dark pool + OTC)
Apr 22, 2026
short_interest
FTD: APLS — 39,752 shares ($1.6M) failed to deliver
Settlement: 20260422, Price: $40.94, FTD Value: $1,627,446.88, APELLIS PHARMACEUTICALS INC CO
Apr 21, 2026
Clinical Trial
Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN
Phase Phase 2 — COMPLETED
Apr 20, 2026
short_interest
FTD: APLS — 14,078 shares ($0.6M) failed to deliver
Settlement: 20260420, Price: $40.90, FTD Value: $575,790.2, APELLIS PHARMACEUTICALS INC CO
Apr 20, 2026
dark_pool
Dark Pool: APLS — 2.4M shares, 21,808 trades
Week starting 2026-04-20. Total ATS volume: 2,399,324 shares across 21,808 trades.
Apr 13, 2026
short_volume
Short Volume: APLS — 61.5% short (2.1M / 3.3M)
Short: 2,059,937 | Exempt: 134 | TRF Vol: 3,347,152 | Short Ratio: 61.5% | Off-exchange volume (dark pool + OTC)
Apr 13, 2026
dark_pool
Dark Pool: APLS — 3.9M shares, 30,619 trades
Week starting 2026-04-13. Total ATS volume: 3,920,540 shares across 30,619 trades.
Apr 7, 2026
short_interest
FTD: APLS — 22,198 shares ($0.9M) failed to deliver
Settlement: 20260407, Price: $40.63, FTD Value: $901,904.74, APELLIS PHARMACEUTICALS INC CO